Get started
Author

Allen Hunt

Observed name: Allen L. Hunt
ORCID: 0000-0002-3945-7070
Observed ORCID: 0000-0002-3945-7070
OpenAlex ID: A5032795065
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia
2021 · Daniel J Rader, Eleftheria Maratos-Flier, et al. · The Journal of Clinical Endocrinology & Metabolism · 69
PDF
A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults
2020 · Antonios O. Aliprantis, Dennis Wolford, et al. · Clinical Pharmacology in Drug Development · 69
Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib
2022 · Ikuo Yamamiya, Allen Hunt, et al. · Clinical Pharmacology in Drug Development · 14
PDF
A 13.2 mg epinephrine intranasal spray demonstrates comparable pharmacokinetics, pharmacodynamics, and safety to a 0.3 mg epinephrine autoinjector
2023 · David A. Dworaczyk, Allen L. Hunt, et al. · Journal of Allergy and Clinical Immunology Global · 13
PDF
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers
2023 · Wei Yin, T. Eric Ballard, et al. · British Journal of Clinical Pharmacology · 12
PDF
Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants
2023 · Ikuo Yamamiya, Allen Hunt, et al. · Clinical Pharmacology in Drug Development · 11
PDF
Evaluation of the Cytochrome P450 3A and P‐glycoprotein Drug‐Drug Interaction Potential of Futibatinib
2023 · Ikuo Yamamiya, Allen Hunt, et al. · Clinical Pharmacology in Drug Development · 11
PDF
Abstract CT125: Evaluation of potential drug-drug interactions (DDIs) between futibatinib and CYP3A inhibitors/inducers, CYP3A substrates, or proton pump inhibitors (PPIs)
2021 · Ikuo Yamamiya, John Laabs, et al. · Cancer Research · 7
EDG-7500, A First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, And Pharmacokinetics In Healthy Adults
2025 · Christopher Dufton, Marc Evanchik, et al. · Journal of Cardiac Failure · 5
5-Period, 5-Treatment Crossover Study to Compare the Pharmacokinetics of Intranasal and Intramuscular Epinephrine Administration in Healthy Adult Participants
2021 · David Dworaczyk, Allen Hunt · Journal of Allergy and Clinical Immunology · 4
PDF
Pharmacokinetic and Pharmacodynamic Effects of Intranasal Epinephrine Versus Intramuscular Epinephrine in Adults
2020 · David Dworaczyk, Allen Hunt · Journal of Allergy and Clinical Immunology · 4
Subanalysis of an Open-Label, Crossover Study to Assess the Relative Bioavailability of Self-administered Nasal Epinephrine Compared to Administration by Trained Health Personnel in Healthy Adult Subjects
2022 · David Dworaczyk, Allen Hunt · Journal of Allergy and Clinical Immunology · 2
P-1245. An Open-Label Phase 1 Study to Evaluate the Effect of Multiple Doses of Rifabutin on the Single-Dose Pharmacokinetics of Ulonivirine in Adults without HIV
2026 · Makeda Robinson, Randolph P Matthews, et al. · Open Forum Infectious Diseases · 1
Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering
2026 · Douglas G. Johns, Maja Skataric, et al. · Clinical Pharmacology & Therapeutics
PDF
Works count: 14
Citation count: 222
H-index: 7
I10-index: 7
Year
Topic
Type